Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are presently covering the firm, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $93.33.

A number of brokerages have recently issued reports on PBH. Royal Bank of Canada boosted their price target on shares of Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a “sector perform” rating in a research note on Friday, March 21st. Oppenheimer lifted their price target on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. StockNews.com cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research note on Tuesday, April 8th. Finally, Canaccord Genuity Group lifted their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, February 7th.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $82.17 on Friday. The business has a 50 day moving average price of $84.56 and a 200 day moving average price of $79.83. Prestige Consumer Healthcare has a fifty-two week low of $62.35 and a fifty-two week high of $90.04. The company has a quick ratio of 2.20, a current ratio of 3.68 and a debt-to-equity ratio of 0.56. The stock has a market cap of $4.07 billion, a price-to-earnings ratio of 19.24, a PEG ratio of 2.69 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. Equities research analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 1.60% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Kayne Anderson Rudnick Investment Management LLC acquired a new position in shares of Prestige Consumer Healthcare in the 4th quarter valued at approximately $84,932,000. Raymond James Financial Inc. acquired a new position in Prestige Consumer Healthcare during the 4th quarter valued at approximately $42,593,000. Norges Bank bought a new position in shares of Prestige Consumer Healthcare during the fourth quarter worth about $40,009,000. Bessemer Group Inc. grew its position in Prestige Consumer Healthcare by 10,053.1% in the 4th quarter. Bessemer Group Inc. now owns 295,050 shares of the company’s stock worth $23,041,000 after purchasing an additional 292,144 shares during the last quarter. Finally, Boston Trust Walden Corp grew its holdings in Prestige Consumer Healthcare by 43.5% in the 4th quarter. Boston Trust Walden Corp now owns 831,627 shares of the company’s stock worth $64,942,000 after buying an additional 252,089 shares in the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.